Kim Campbell Selected Research

COVID-19

1/2021

Primary Prophylaxis With Biosimilar Filgrastim for Patients at Intermediate Risk for Febrile Neutropenia: A Cost-Effectiveness Analysis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kim Campbell Research Topics

Disease

8	Neoplasms (Cancer) 06/2022 - 10/2017
8	Febrile Neutropenia 01/2022 - 01/2018
5	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2023 - 04/2014
3	Breast Neoplasms (Breast Cancer) 09/2021 - 01/2021
3	Chemotherapy-Induced Febrile Neutropenia 08/2020 - 10/2017
2	Rheumatoid Arthritis 10/2022 - 01/2022
2	Arthritis (Polyarthritis) 10/2022 - 01/2020
2	Autoimmune Diseases (Autoimmune Disease) 01/2022 - 12/2004
2	Non-Hodgkin Lymphoma (Lymphosarcoma) 09/2021 - 01/2020
2	Psoriatic Arthritis 01/2020 - 10/2019
2	Neutropenia 01/2018 - 10/2017
1	Coronary Artery Disease (Coronary Atherosclerosis) 01/2024
1	Inflammation (Inflammations) 01/2024
1	Cicatrix (Scar) 01/2023
1	Experimental Arthritis 01/2022
1	Disease Progression 01/2022
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2021
1	COVID-19 01/2021
1	Lung Neoplasms (Lung Cancer) 01/2020
1	Necrosis 01/2020
1	Spondylitis 01/2020
1	Fatigue 01/2020
1	Pain (Aches) 01/2020
1	Joint Diseases (Joint Disease) 10/2019
1	Skin Diseases (Skin Disease) 10/2019
1	Axial Spondyloarthritis 01/2019
1	Infections 01/2018
1	Fever (Fevers) 01/2018
1	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 10/2012
1	Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker) 09/2010

Drug/Important Bio-Agent (IBA)

9	Biosimilar PharmaceuticalsIBA 01/2021 - 10/2017
7	Ustekinumab (CNTO 1275)FDA Link 01/2023 - 12/2016
7	Filgrastim (Neupogen)FDA Link 01/2021 - 10/2017
6	pegfilgrastim (Neulasta)FDA Link 09/2021 - 10/2017
4	Colony-Stimulating Factors (Colony Stimulating Factor)IBA 01/2021 - 01/2018
3	Interleukin-23 (Interleukin 23)IBA 01/2023 - 04/2014
3	Interleukin-17 (Interleukin 17)IBA 01/2023 - 04/2014
3	AntigensIBA 10/2022 - 01/2020
3	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2022 - 10/2017
3	Interleukin-12 (IL 12)IBA 01/2021 - 12/2016
2	Biomarkers (Surrogate Marker)IBA 01/2024 - 01/2022
2	CytokinesIBA 01/2023 - 10/2019
2	guselkumabIBA 01/2023 - 04/2014
2	Peptides (Polypeptides)IBA 10/2022 - 01/2022
1	LipopolysaccharidesIBA 01/2024
1	CalciumIBA 01/2024
1	Calcitriol (Calcijex)FDA LinkGeneric 10/2022
1	serum P-component (CIt)IBA 10/2022
1	AntibodiesIBA 10/2022
1	Liposomes (Liposome)IBA 10/2022
1	Proteins (Proteins, Gene)FDA Link 10/2022
1	Human Growth Hormone (Saizen)FDA LinkGeneric 06/2022
1	EpitopesIBA 01/2022
1	Collagen Type II (Type II Collagen)IBA 01/2022
1	HLA-DR Antigens (HLA-DR)IBA 01/2022
1	Monoclonal AntibodiesIBA 01/2021
1	InterferonsIBA 01/2021
1	pembrolizumabIBA 08/2020
1	HLA-B27 Antigen (HLA B27 Antigen)IBA 01/2020
1	Etoposide (VP 16)FDA LinkGeneric 01/2020
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2020
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2020
1	C-Reactive ProteinIBA 10/2019
1	Etanercept (Enbrel)FDA Link 01/2019
1	HLA-C Antigens (HLA-C)IBA 12/2016
1	Prednisone (Sone)FDA LinkGeneric 09/2010
1	Adrenal Cortex Hormones (Corticosteroids)IBA 09/2010
1	deflazacortIBA 09/2010

Therapy/Procedure

8	Drug Therapy (Chemotherapy) 01/2022 - 01/2018
6	Therapeutics 06/2022 - 09/2010
2	Immunotherapy 10/2022 - 01/2022
1	Immunomodulation 10/2022
1	Injections 01/2020
1	Photopheresis 10/2012
1	Oral Administration 12/2004